Design of hybrid β-hairpin peptides with enhanced cell specificity and potent anti-inflammatory activity

Biomaterials

Volumn 34, Issue 1, 2013, Pages 237-250

  Liu, YiFan ^a   Xia, Xi ^a   Xu, Liang ^b   Wang, YiZhen ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Hairpin; Anti inflammatory; Antibacterial activity; Antimicrobial peptides; Bactericidal mechanism; Hemolysis

Indexed keywords

ANTI-BACTERIAL ACTIVITY; ANTI-INFLAMMATORIES; ANTI-INFLAMMATORY ACTIVITY; ANTI-INFLAMMATORY AGENTS; ANTI-MICROBIAL ACTIVITY; ANTIMICROBIAL PEPTIDE; BACTERIAL RESISTANCE; CECROPIN; CHEMOATTRACTANTS; CHEMOKINES; GEL RETARDATION; GRAM-NEGATIVE BACTERIA; HEMOLYSIS; HIGH AFFINITY; HIGH SELECTIVITY; HYBRID PEPTIDES; INDUCIBLE NITRIC OXIDE SYNTHASE (INOS); LACTOFERRICIN; MICROBIAL CELLS; PROINFLAMMATORY CYTOKINES; RED BLOOD CELL; TRANSMISSION ELECTRON MICROSCOPY TEM; TUMOR NECROSIS FACTORS;

BACTERIA; BLOOD; CELL MEMBRANES; CYTOLOGY; MACROPHAGES; NITRIC OXIDE; PEPTIDES; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

POLYPEPTIDES;

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CECROPIN A; DNA; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTOFERRICIN; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYPEPTIDE ANTIBIOTIC AGENT; PROGETRIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BETA HAIRPIN; BINDING AFFINITY; CELL MEMBRANE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA BINDING; DRUG DESIGN; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; ERYTHROCYTE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SWINE; TRANSMISSION ELECTRON MICROSCOPY;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; BACTERIA; CATTLE; CELL DEATH; CELL LINE; CELL MEMBRANE; CELL SURVIVAL; CIRCULAR DICHROISM; DNA; DRUG DESIGN; DRUG SYNERGISM; HEMOLYSIS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; PROTEOLYSIS; SUS SCROFA; TUMOR NECROSIS FACTOR-ALPHA;

BACTERIA (MICROORGANISMS); BOVINAE; NEGIBACTERIA; POSIBACTERIA; SUS;

EID: 84868131857     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.09.032     Document Type: Article

References (55)

1. Auvynet C., Rosenstein Y. Multifunctional host defense peptides: antimicrobial peptides, the small yet big players in innate and adaptive immunity. FEBS J 2009, 276:6497-6508.
2. Hancock R.E., Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biothechnol 2006, 24:1551-1557.
3. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002, 24:389-395.
4. Hancock R.E.W. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001, 1:156-164.
5. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers 2002, 66:236-248.
6. Yeaman M.R., Yount N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003, 55:27-55.
7. Navon-Venezia S., Feder R., Gaidukov L., Carmeli Y., Mor A. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob Agents Chemother 2002, 46:689-694.
8. Bell A. Antimalarial peptides: the long and the short of it. Curr Pharm Des 2011, 17:2719-2731.
9. Shukla A., Fleming K.E., Chuang H.F., Chau T.M., Loose C.R., Stephanopoulos G.N., et al. Controlling the release of peptide antimicrobial agents from surfaces. Biomaterials 2010, 31:2348-2357.
10. Wiradharma N., Khan M., Yong L.K., Hauser C.A., Seow S.V., Zhang S., et al. The effect of thiol functional group incorporation into cationic helical peptides on antimicrobial activities and spectra. Biomaterials 2011, 32:9100-9108.
11. Chen C., Hu J., Zhang S., Zhou P., Zhao X., Xu H., et al. Molecular mechanisms of antibacterial and antitumor actions of designed surfactant-like peptides. Biomaterials 2012, 33:592-603.
12. Wiradharma N., Khoe U., Hauser C.A., Seow S.V., Zhang S., Yang Y.Y. Synthetic cationic amphiphilic α-helical peptides as antimicrobial agents. Biomaterials 2011, 32:2204-2212.
13. Hilpert K., Elliott M.R., Volkmer-Engert R., Henklein P., Donini O., Zhou Q., et al. Sequence requirements and an optimization strategy for short antimicrobial peptides. Chem Biol 2006, 13:1101-1107.
14. Chou H.T., Kuo T.Y., Chiang J.C., Pei M.J., Yang W.T., Yu H.C., et al. Design and synthesis of cationic antimicrobial peptides with improved activity and selectivity against Vibrio spp. Int J Antimicrob Agents 2008, 32:130-138.
15. Blondelle S.E., Lohner K. Optimization and high-throughput screening of antimicrobial peptides. Curr Pharm Des 2010, 16:3204-3211.
16. Park K.H., Nan Y.H., Park Y., Kim J.I., Park I.S., Hahm K.S., et al. Cell specificity, anti-inflammatory activity, and plausible bactericidal mechanism of designed Trp-rich model antimicrobial peptides. Biochim Biophys Acta 2009, 1788:1193-1203.
17. Saugar J.M., Rodríguez-Hernández M.J., de la Torre B.G., Pachón-lbaňez M.E., Fernández-Reyes M., Andreu D., et al. Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action. Antimicrob Agents Chemother 2006, 50:1251-1256.
18. Liu Y.F., Luan C., Xia X., An S., Wang Y.Z. Antibacterial activity, cytotoxicity and mechanisms of action of cathelicidin peptides against enteric pathogens in weaning piglets. Int J Pept Res Ther 2011, 17:175-184.
19. Liu Y.F., Han F.F., Xie Y.G., Wang Y.Z. Comparative antimicrobial activity and mechanism of action of bovine lactoferricin-derived synthetic peptides. Biometals 2011, 24:1069-1078.
20. Sipos D., Chandrasekhar K., Arvidsson K., Engström A., Ehrenberg A. Two-dimensional proton-NMR studies on a hybrid peptide between cecropin A and melittin. Eur J Biochem 1991, 19:285-291.
21. Wiegand I., Hilpert K., Hancock R.E. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 2008, 3:163-175.
22. Park C.B., Kim H.S., Kim S.C. Mechanism of action of the antimicrobial peptide Buforin || kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 2008, 244:253-257.
23. Ulvatne H., Samuelsen Ø., Haukland H.H., Krämer M., Vorland L.H. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol Lett 2004, 237:377-384.
24. Cassone M., Otvos L. Synergy among antibacterial peptides and between peptides and small-molecule antibiotics. Expert Rev Anti Infect Ther 2010, 8:703-716.
25. Mani R., Cady S.D., Tang M., Waring A.J., Lehrer R.I., Hong M. Membrane-dependent oligomeric structure and pore formation of a β-hairpin antimicrobial peptide in lipid bilayers from solid-state NMR. Proc Natl Acad Sci U S A 2006, 103:16242-16247.
26. Brandl K., Plitas G., Mihu C.N., Ubeda C., Jia T., Fleisher M., et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 2008, 455:804-807.
27. Jernberg C., Löfmark S., Edlund C., Jansson J.K. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 2010, 156:3216-3223.
28. Williams D.F. On the mechanisms of biocompatibility. Biomaterials 2008, 29:2941-2953.
29. Bell G., Gouyon P.H. Arming the enemy: the evolution of resistance to self-proteins. Microbiology 2003, 149:1367-1375.
30. Jin Y., Hammer J., Pate M., Zhang Y., Zhu F., Zmuda E., et al. Antimicrobial activities and structures of two linear cationic peptide families with various amphipathic β-hairpin and α-helical potentials. Antimicrob Agents Chemother 2005, 49:4957-4964.
31. Jiang Z., Vasil A.I., Gera L., Vasil M.L., Hodges R.S. Rational design of α-helical antimicrobial peptides to target Gram-negative pathogens, Acinetobacter baumannii and Pseudomonas aeruginosa: utilization of charge, 'specificity determinants', total hydrophobicity, hydrophobe type and location as design parameters to improve the therapeutic ratio. Chem Biol Drug Des 2011, 77:225-240.
32. Dathe M., Wieprecht T. Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim Biophys Acta 1999, 1462:71-87.
33. Giangaspero A., Sandri L., Tossi A. Amphipathic α-helical antimicrobial peptides. Eur J Biochem 2001, 268:5589-5600.
34. Andreu D., Ubach J., Boman A., Wåhlin B., Wade D., Merrifield R.B., et al. Shortened cecropin A-melittin hybrids. Significant size reduction retains potent antibiotic activity. FEBS Lett 1992, 296:190-194.
35. Chicharro C., Granata C., Lozano R., Andreu D., Rivas L. N-terminal fatty acid substitution increases the leishmanicidal activity of CA(1-7)M(2-9), a cecropin-melittin hybrid peptide. Antimicrob Agents Chemother 2001, 45:2441-2449.
36. Fox M.A., Thwaite J.E., Ulaeto D.O., Atkins T.P., Atkins H.S. Design and characterization of novel hybrid antimicrobial peptides based on cecropin A, LL-37 and magainin ||. Peptides 2012, Available from:. http://www.sciencedirect.com/science/article/pii/S0196978112000344, 10.1016/j.peptides.2012.01.013.
37. Chen Y., Guarnieri M.T., Vasil Al, Vasil M.L., Mant C.T., Hodges R.S. Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides. Antimicrob Agents Chemother 2007, 51:1398-1406.
38. Kim S., Kim S.S., Lee B.J. Correlation between the activities of alpha-helical antimicrobial peptides and hydrophobicities represented as RP HPLC retention times. Peptides 2005, 26:2050-2056.
39. Laverty G., McLaughlin M., Shaw C., Gorman S.P., Gilmore B.F. Antimicrobial activity of short, synthetic cationic lipopeptides. Chem Biol Drug Des 2010, 75:563-569.
40. Sato H., Feix J.B. Peptide-membrane interactions and mechanisms of membrane destruction by amphipathic alpha-helical antimicrobial peptides. Biochim Biophys Acta 2006, 1758:1245-1256.
41. Hsu C.H., Chen C., Jou M.L., Lee A.Y., Lin Y.C., Yu Y.P., et al. Structural and DNA-binding studies on the bovine antimicrobial peptide, indolicidin: evidence for multiple conformations involved in binding to membranes and DNA. Nucleic Acids Res 2005, 33:4053-4064.
42. Cirioni O., Giacometti A., Kamysz W., Silvestri C., Riva A., Della Vittoria A., et al. In vitro activities of tachyplesin ||| against Pseudomonas aeruginosa. Peptide 2007, 28:747-751.
43. Gobbo M., Benincasa M., Bertoloni G., Biondi B., Dosselli R., Papini E., et al. Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. J Med Chem 2009, 52:5197-5206.
44. Nguyen L.T., Chau J.K., Perry N.A., de Boer L., Zaat S.A., Vogel H.J. Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS One 2010, 5:e12684.
45. Rozek A., Powers J.P., Friedrich C.L., Hancock R.E. Structure-based design of an indolicidin peptide analogue with increased protease stability. Biochemistry 2003, 42:14130-14138.
46. Lai Y.P., Gallo R.L. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Cell 2009, 30:131-141.
47. Rosenfeld Y., Shai Y. Lipopolysaccharide (Endotoxin)-host defense antimicrobial peptides interactions: role in bacterial resistance and prevention of sepsis. Biochim Biophys Acta 2006, 1758:1513-1522.
48. Zughaier S.M., Shafer W.M., Stephens D.S. Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell Microbiol 2005, 7:1251-1262.
49. Nagaoka I., Hirota S., Niyonsaba F., Hirata M., Adachi Y., Tamura H., et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells. J Immunol 2001, 167:3329-3338.
50. Nan Y.H., Bang J.K., Shin S.Y. Design of novel indolicidin-derived antimicrobial peptides with enhanced cell specificity and potent anti-inflammatory activity. Peptides 2009, 30:832-838.
51. Motzkus D., Schulz-Maronde S., Heitland A., Schulz A., Forssmann W.G., Jübner M., et al. The novel β-defensin DEFB123 prevents lipopolysaccharide-mediated effects in vitro and in vivo. FASEB J 2006, 20:1701-1702.
52. Buxadé M., Lunazzi G., Minguillón J., Iborra S., Berga-Bolaños R., Del Val M., et al. Gene expression induced by Toll-like receptors in macrophages requires the transcription factor NFA T5. J Exp Med 2012, 209:379-393.
53. Niyonsaba F., Ushio H., Nakano N., Nq W., Sayama K., Hashimoto K., et al. Antimicrobial peptides human β-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol 2007, 127:594-604.
54. Brueckmann M., Hoffmann U., Dvortsak E., Lang S., Kaden J.J., Borggrefe M., et al. Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis. Inflamm Res 2004, 53:528-533.
55. Weber N.C., Blumenthal S.B., Hartung T., Vollmar A.M., Kiemer A.K. ANP inhibits TNF-α-induced endothelial MCP-1 expression-involvement of p38 MAPK and MKP-1. J Leukoc Biol 2003, 74:932-941.